260 related articles for article (PubMed ID: 20642381)
1. Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist.
Var T; Tonguc E; Dogan M; Mollamahmutoglu L
Gynecol Endocrinol; 2011 Aug; 27(8):558-61. PubMed ID: 20642381
[TBL] [Abstract][Full Text] [Related]
2. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
[TBL] [Abstract][Full Text] [Related]
3. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
4. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
[TBL] [Abstract][Full Text] [Related]
5. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
6. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
7. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles.
Wu Z; Li R; Ma Y; Deng B; Zhang X; Meng Y; Chen X; Liu P; Qiao J
Reprod Biomed Online; 2012 May; 24(5):511-20. PubMed ID: 22417667
[TBL] [Abstract][Full Text] [Related]
8. The effects of peak and mid-luteal estradiol levels on in vitro fertilization outcome.
Moraloğlu Ö; Tonguc EA; Özel M; Özakşit G; Var T; Sarikaya E
Arch Gynecol Obstet; 2012 Mar; 285(3):857-62. PubMed ID: 21938500
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of GnRH agonists and antagonists in an ovular donation program].
Saucedo de la Llata E; Moraga Sánchez MR; Batiza Reséndiz V; Santos Haliscak R; Galache Vega P; Hernández Ayup S
Ginecol Obstet Mex; 2004 Feb; 72():53-6. PubMed ID: 15216901
[TBL] [Abstract][Full Text] [Related]
10. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
Ren J; Sha A; Han D; Li P; Geng J; Ma C
Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
[TBL] [Abstract][Full Text] [Related]
11. Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH).
Chen QJ; Sun XX; Li L; Gao XH; Wu Y; Gemzell-Danielsson K; Cheng LN
Acta Obstet Gynecol Scand; 2007; 86(7):849-54. PubMed ID: 17611831
[TBL] [Abstract][Full Text] [Related]
12. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program.
Erb TM; Vitek W; Wakim AN
Fertil Steril; 2010 Feb; 93(2):374-8. PubMed ID: 19171336
[TBL] [Abstract][Full Text] [Related]
14. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles.
Xu B; Li Z; Zhang H; Jin L; Li Y; Ai J; Zhu G
Fertil Steril; 2012 Jun; 97(6):1321-7.e1-4. PubMed ID: 22494924
[TBL] [Abstract][Full Text] [Related]
15. Triggering final oocyte maturation with reduced doses of hCG in IVF/ICSI: a prospective, randomized and controlled study.
Lin H; Wang W; Li Y; Chen X; Yang D; Zhang Q
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):143-7. PubMed ID: 21824709
[TBL] [Abstract][Full Text] [Related]
16. Elevated E2: oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate.
Yang JH; Chen HF; Lien YR; Chen SU; Ho HN; Yang YS
J Reprod Med; 2001 May; 46(5):434-8. PubMed ID: 11396368
[TBL] [Abstract][Full Text] [Related]
17. High serum estradiol levels are not detrimental to in vitro fertilization outcome.
Wu CH; Kuo TC; Wu HH; Yeh GP; Tsai HD
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):54-9. PubMed ID: 17389191
[TBL] [Abstract][Full Text] [Related]
18. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
Berin I; Stein DE; Keltz MD
Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
[TBL] [Abstract][Full Text] [Related]
20. Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles.
Seval MM; Özmen B; Atabekoğlu C; Şükür YE; Şimşir C; Kan Ö; Sönmezer M
J Obstet Gynaecol Res; 2016 Sep; 42(9):1146-51. PubMed ID: 27199084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
